EDISON EQUITY RESEARCH - TRIMEL PHARMACEUTICALS
2014年12月1日 - 10:34PM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH:
TRIMEL PHARMACEUTICALS - ENDO TO
PARTNER NATESTO
Trimel is partnering its Natesto intranasal gel testosterone
replacement therapy (TRT) product in the US and Mexico with Endo
Pharmaceuticals, receiving US$25m upfront and a tiered supply price
for manufacturing. Endo’s marketed portfolio of TRT products makes
it an ideal partner, and Trimel expects to be ready for commercial
manufacturing in Q115.
Trimel is a Canadian specialty pharmaceutical company. Natesto and
Tefina deliver testosterone through a bio-adhesive nasal gel drug
delivery technology platform, for male hypogonadism and female
orgasmic disorder (FOD), respectively. Estrace is being marketed
for HRT in Canada.
To view our full report, please click here:
http://www.edisoninvestmentresearch.com/research/report/trimel-pharmaceuticals6
Click here to view all of Edison
Investment Research’s published reports
Trilogy International Pa... (TSX:TRL)
過去 株価チャート
から 5 2024 まで 6 2024
Trilogy International Pa... (TSX:TRL)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Trilogy International Partners Inc (トロント証券取引所): 0 recent articles
その他のTrimel Pharmaceuticals Corpニュース記事